Literature DB >> 22764360

Premenstrual dysphoric disorder: evidence for a new category for DSM-5.

C Neill Epperson1, Meir Steiner, S Ann Hartlage, Elias Eriksson, Peter J Schmidt, Ian Jones, Kimberly A Yonkers.   

Abstract

Premenstrual dysphoric disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSMIV, "Criterion Sets and Axes Provided for Further Study." Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding the appropriate criteria and placement for the disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.

Entities:  

Mesh:

Year:  2012        PMID: 22764360      PMCID: PMC3462360          DOI: 10.1176/appi.ajp.2012.11081302

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  96 in total

1.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.

Authors:  K S Kendler; L M Karkowski; L A Corey; M C Neale
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

2.  Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.

Authors:  M Steiner; M Korzekwa; J Lamont; A Wilkins
Journal:  Psychopharmacol Bull       Date:  1997

3.  Biological, social, and behavioral factors associated with premenstrual syndrome.

Authors:  P A Deuster; T Adera; J South-Paul
Journal:  Arch Fam Med       Date:  1999 Mar-Apr

4.  Progesterone metabolite allopregnanolone in women with premenstrual syndrome.

Authors:  A J Rapkin; M Morgan; L Goldman; D W Brann; D Simone; V B Mahesh
Journal:  Obstet Gynecol       Date:  1997-11       Impact factor: 7.661

5.  Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; M A Danaceau; L F Adams; D R Rubinow
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

6.  Premenstrual syndrome: evidence for symptom stability across cycles.

Authors:  M Bloch; P J Schmidt; D R Rubinow
Journal:  Am J Psychiatry       Date:  1997-12       Impact factor: 18.112

7.  Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

Authors:  I Sundström; A Andersson; S Nyberg; D Ashbrook; R H Purdy; T Bäckström
Journal:  Neuroendocrinology       Date:  1998-02       Impact factor: 4.914

8.  Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls.

Authors:  M Bloch; P J Schmidt; T P Su; M B Tobin; D R Rubinow
Journal:  Biol Psychiatry       Date:  1998-06-15       Impact factor: 13.382

9.  Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects.

Authors:  I Sundström; T Bäckström
Journal:  Biol Psychiatry       Date:  1998-10-15       Impact factor: 13.382

10.  Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome.

Authors:  L Seippel; T Bäckström
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

View more
  77 in total

Review 1.  Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder.

Authors:  Erika Comasco; Inger Sundström-Poromaa
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

2.  Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder.

Authors:  C Neill Epperson; Liisa V Hantsoo
Journal:  Am J Psychiatry       Date:  2017-01-01       Impact factor: 18.112

3.  Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis.

Authors:  K M Schmalenberger; T A Eisenlohr-Moul; P Surana; D R Rubinow; S S Girdler
Journal:  Psychol Med       Date:  2017-02-14       Impact factor: 7.723

4.  Evaluation and Treatment of the Angry Patient.

Authors:  Fallon Chipidza; Rachel S Wallwork; Traci N Adams; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2016-06-23

5.  Personal history of major depression may put women at risk for premenstrual dysphoric symptomatology.

Authors:  Eynav E Accortt; Anya V Kogan; John J B Allen
Journal:  J Affect Disord       Date:  2013-06-22       Impact factor: 4.839

6.  Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS).

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

7.  Premenstrual dysphoric disorder and the brain.

Authors:  C Neill Epperson
Journal:  Am J Psychiatry       Date:  2013-03       Impact factor: 18.112

Review 8.  Neuroendocrine pathways underlying risk and resilience to PTSD in women.

Authors:  Meghna Ravi; Jennifer S Stevens; Vasiliki Michopoulos
Journal:  Front Neuroendocrinol       Date:  2019-09-19       Impact factor: 8.606

9.  BDNF Val66Met polymorphism and brain-derived neurotrophic factor levels across the female life span: implications for the sex bias in affective disorders.

Authors:  C Neill Epperson; Tracy L Bale
Journal:  Biol Psychiatry       Date:  2012-09-15       Impact factor: 13.382

10.  Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders.

Authors:  Geoffrey M Reed; Michael B First; Cary S Kogan; Steven E Hyman; Oye Gureje; Wolfgang Gaebel; Mario Maj; Dan J Stein; Andreas Maercker; Peter Tyrer; Angelica Claudino; Elena Garralda; Luis Salvador-Carulla; Rajat Ray; John B Saunders; Tarun Dua; Vladimir Poznyak; María Elena Medina-Mora; Kathleen M Pike; José L Ayuso-Mateos; Shigenobu Kanba; Jared W Keeley; Brigitte Khoury; Valery N Krasnov; Maya Kulygina; Anne M Lovell; Jair de Jesus Mari; Toshimasa Maruta; Chihiro Matsumoto; Tahilia J Rebello; Michael C Roberts; Rebeca Robles; Pratap Sharan; Min Zhao; Assen Jablensky; Pichet Udomratn; Afarin Rahimi-Movaghar; Per-Anders Rydelius; Sabine Bährer-Kohler; Ann D Watts; Shekhar Saxena
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.